TR200000532T2 - Salgılanan proteinleri kodlayan genler kullanılan terapiler için yöntemler ve bileşimler. - Google Patents

Salgılanan proteinleri kodlayan genler kullanılan terapiler için yöntemler ve bileşimler.

Info

Publication number
TR200000532T2
TR200000532T2 TR2000/00532T TR200000532T TR200000532T2 TR 200000532 T2 TR200000532 T2 TR 200000532T2 TR 2000/00532 T TR2000/00532 T TR 2000/00532T TR 200000532 T TR200000532 T TR 200000532T TR 200000532 T2 TR200000532 T2 TR 200000532T2
Authority
TR
Turkey
Prior art keywords
methods
compositions
therapies
genes encoding
secreted proteins
Prior art date
Application number
TR2000/00532T
Other languages
English (en)
Inventor
G. Barsoum James
Qin Xiao-Qiang
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR200000532T2 publication Critical patent/TR200000532T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bir memeli alicinin hücrelerinin insan interferonu gibi bir salgilanmis proteini kodlayan DNA ile in situ tadil edilmesi için yöntemler ve farmasötik bilesimler temin edilmistir. Yöntemler, in vivo ya da eks vivo bir salgilanmis protein sentezleme sisteminin olusturulmasi ve sentezleme sisteminin memeli aliciya tatbik edilmesini kapsamaktadir. Sentezleme sistemi ve yöntemler interferonlarin lokalize ve sistemik in situ verilmesi için yararli olmaktadir.
TR2000/00532T 1997-08-29 1998-08-25 Salgılanan proteinleri kodlayan genler kullanılan terapiler için yöntemler ve bileşimler. TR200000532T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
TR200000532T2 true TR200000532T2 (tr) 2000-11-21

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00532T TR200000532T2 (tr) 1997-08-29 1998-08-25 Salgılanan proteinleri kodlayan genler kullanılan terapiler için yöntemler ve bileşimler.

Country Status (24)

Country Link
EP (1) EP1007717B8 (tr)
JP (3) JP4124565B2 (tr)
KR (1) KR100699285B1 (tr)
CN (1) CN100342019C (tr)
AT (1) ATE316145T1 (tr)
AU (1) AU740428B2 (tr)
BR (1) BR9812138A (tr)
CA (1) CA2300480C (tr)
CY (1) CY1105029T1 (tr)
CZ (2) CZ299095B6 (tr)
DE (1) DE69833264T2 (tr)
DK (1) DK1007717T3 (tr)
EA (1) EA003256B1 (tr)
EE (1) EE04873B1 (tr)
ES (1) ES2257817T3 (tr)
HU (1) HU224422B1 (tr)
IL (2) IL134593A0 (tr)
IS (1) IS2318B (tr)
NO (1) NO20000990L (tr)
NZ (1) NZ503401A (tr)
PT (1) PT1007717E (tr)
SK (1) SK286821B6 (tr)
TR (1) TR200000532T2 (tr)
WO (1) WO1999010516A2 (tr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60219142T2 (de) * 2001-01-22 2007-12-13 Biogen Idec Ma Inc., Cambridge Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
US20220364122A1 (en) * 2019-06-01 2022-11-17 Sivec Biotechnologies Llc Bacterial platform for delivery of gene-editing systems to eukaryotic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
AU711269B2 (en) * 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
IL134593A (en) 2007-06-17
EE04873B1 (et) 2007-08-15
EP1007717A2 (en) 2000-06-14
SK2482000A3 (en) 2000-08-14
EP1007717B1 (en) 2006-01-18
PT1007717E (pt) 2006-06-30
HUP0002913A2 (hu) 2000-12-28
EP1007717B8 (en) 2006-05-03
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
CZ2000733A3 (cs) 2000-06-14
ATE316145T1 (de) 2006-02-15
CA2300480C (en) 2010-01-05
DE69833264D1 (de) 2006-04-06
BR9812138A (pt) 2000-07-18
NZ503401A (en) 2003-01-31
IS5374A (is) 2000-02-11
WO1999010516A2 (en) 1999-03-04
JP2001514010A (ja) 2001-09-11
KR20010023511A (ko) 2001-03-26
IL134593A0 (en) 2001-04-30
ES2257817T3 (es) 2006-08-01
EA003256B1 (ru) 2003-02-27
JP2004155786A (ja) 2004-06-03
NO20000990D0 (no) 2000-02-28
JP4219335B2 (ja) 2009-02-04
SK286821B6 (sk) 2009-06-05
JP4124565B2 (ja) 2008-07-23
NO20000990L (no) 2000-05-02
EE200000102A (et) 2000-12-15
JP2005225888A (ja) 2005-08-25
HUP0002913A3 (en) 2003-08-28
CZ297314B6 (cs) 2006-11-15
KR100699285B1 (ko) 2007-03-26
CA2300480A1 (en) 1999-03-04
AU9205198A (en) 1999-03-16
CN100342019C (zh) 2007-10-10
CY1105029T1 (el) 2010-03-03
IS2318B (is) 2007-11-15
DK1007717T3 (da) 2006-05-29
EA200000270A1 (ru) 2000-10-30
JP3953458B2 (ja) 2007-08-08
WO1999010516A3 (en) 1999-05-06
CN1271391A (zh) 2000-10-25
CZ299095B6 (cs) 2008-04-23
HU224422B1 (hu) 2005-08-29
DE69833264T2 (de) 2006-09-28

Similar Documents

Publication Publication Date Title
AU2001278797A1 (en) Expression vector using for animal cell
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
ES2149774T3 (es) Aportacion dirigida de genes que codifican proteinas secretoras.
UA84387C2 (ru) Человеческий цитокин как лиганд зальфа рецептора и его применение
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
FR2763943B1 (fr) Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
FI972514A7 (fi) Kasvainspesifisten sytotoksisten T-solujen in vivo aktivointi
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
DE69528170D1 (de) Intrazelluläre verabreichung therapeutischer sustanzenmittels virosomen
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ATE321768T1 (de) Linker-nucleosid, seine herstellung und verwendung
DE60033679D1 (de) Herstellung von rekombinanten adenoviren und von adenovirus-genbanken
FR2774990B1 (fr) Nouveaux peptides, utilisation en therapeutique et compositions pharmaceutiques les renfermant
UA72877C2 (en) Modulators of metabolic ways of intracellular inflammation, cells death and survival